Corroborating this idea, a research carried out in Germany used the patient registry to calculate the financial costs, for 1 year, to treat patients diagnosed with schizophrenia, with or without pharmacogenetic analysis for polymorphisms in the CYP2D6 genes. The gene discussed is CYP2D6; the disease is schizophrenia.